GPR91 antagonist and TGF-β inhibitor suppressed collagen production of high glucose and succinate induced HSC activation.


Journal

Biochemical and biophysical research communications
ISSN: 1090-2104
Titre abrégé: Biochem Biophys Res Commun
Pays: United States
ID NLM: 0372516

Informations de publication

Date de publication:
17 09 2020
Historique:
received: 27 07 2020
accepted: 29 07 2020
pubmed: 17 8 2020
medline: 26 2 2021
entrez: 17 8 2020
Statut: ppublish

Résumé

Activated hepatic stellate cells (HSCs) play a central role in fibrillary collagen production, the primary cause of liver fibrosis. Although it is known that primary cultured HSCs are activated by plastic culture dish stiffness, HSC activation and quiescent-state-reversion mechanisms are still unclear. In this study, we used cultured normal rat HSCs on 3.2 kPa collagen normal liver stiffness equivalent gel, to determine whether high glucose or high succinate conditions induce HSC activation, and examined whether activated HSCs reverted to a quiescent state when suppressed by GPR91 antagonists or TGF-β1 receptor inhibitors. We measured the gene expression levels of α-SMA and type I collagen HSC activation markers using real-time PCR. Our data indicated that high glucose conditions induced HSC activation, and showed that under continuous high glucose exposure HSC activation progressed. A GPR91 antagonist, 2 d, and a TGF-β1 receptor inhibitor, SB525334, suppressed the Col1α mRNA expression level of these activated HSCs. Similarly, under extended high succinate exposure, 2 d and SB525334 reduced Col1α mRNA expression levels of activated HSCs. From the above, we determined that even though HSCs had already been activated by high glucose or succinate conditions which persisted after activation, the GPR91 antagonist and the TGF-β1 receptor inhibitor were able to reduce the production of type I collagen from activated HSCs.

Identifiants

pubmed: 32798017
pii: S0006-291X(20)31542-4
doi: 10.1016/j.bbrc.2020.07.141
pii:
doi:

Substances chimiques

6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline 0
Imidazoles 0
Quinoxalines 0
Receptors, G-Protein-Coupled 0
Sucnr1 protein, rat 0
Transforming Growth Factor beta 0
Collagen 9007-34-5
Succinic Acid AB6MNQ6J6L
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

362-366

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mutsuko Sakai (M)

Department of Applied Biology, Kyoto Institute of Technology, Sakyo-ku, Kyoto, 606 8585, Japan. Electronic address: CXC06632@nifty.com.

Takaaki Sumiyoshi (T)

Department of Chemistry and Materials Engineering, Kansai University, Suita, Osaka, 564 8680, Japan.

Takuma Aoyama (T)

Department of Macromolecular Science and Engineering, Kyoto Institute of Technology, Sakyo-ku, Kyoto, 606 8585, Japan.

Kenji Urayama (K)

Department of Macromolecular Science and Engineering, Kyoto Institute of Technology, Sakyo-ku, Kyoto, 606 8585, Japan.

Ryoichi Yoshimura (R)

Department of Applied Biology, Kyoto Institute of Technology, Sakyo-ku, Kyoto, 606 8585, Japan.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH